Advertisement
Corrigendum
Open Access |
10.1172/JCI213400
Find articles by Shieh, A. in: PubMed | Google Scholar
Find articles by
Epeldegui, M.
in:
PubMed
|
Google Scholar
|
Find articles by
Karlamangla, A.
in:
PubMed
|
Google Scholar
|
Find articles by
Jones, R.
in:
PubMed
|
Google Scholar
|
Find articles by
Pacifici, R.
in:
PubMed
|
Google Scholar
|
Find articles by Greendale, G. in: PubMed | Google Scholar
Published November 2, 2026 - More info
BACKGROUND In female murine models, one source of inflammation is a menopause-related increase in gut permeability. We examined whether the menopause transition (MT) in women is associated with an increase in markers of gut epithelial dysfunction and gut microbial product translocation, signals of compromised gut epithelial barrier integrity.METHODS In 964 women, we measured markers of gut epithelial dysfunction (fatty acid binding protein 2, FABP2) and gut microbial antigen translocation (soluble CD14, sCD14) using sera collected before, during, and after the MT. Multivariable mixed effects regressions fit piecewise linear models to repeated FABP2 or sCD14 measures relative to time from final menstrual period (FMP). Covariates were age at FMP, race and ethnicity, and BMI.RESULTS FABP2 and sCD14 did not change significantly until 2.5 years pre-FMP. At that point, FABP2 began rising; sCD14 began increasing 6 months later. FABP2 and sCD14 peaked 6 and 6.5 years after FMP, respectively; subsequent levels remained stable. During the ~9-year interval of MT-related gain in gut barrier compromise markers, annual FABP2 and sCD14 increases were 2.6% (95% CI: 1.7% to 3.4%) and 0.8% (95% CI: 0.6% to 1.1%), respectively, among White women with sample-average BMI and age at FMP. FABP2 and sCD14 change rates did not differ significantly by race and ethnicity, BMI, or age at FMP.CONCLUSION The MT is associated with a rise in markers of compromised gut barrier integrity, suggesting that this pathway of inflammation, previously described in animal models, occurs in humans.FUNDING NIH U01NR004061, U01AG012505, U01AG012535, U01AG012531, U01AG012539, U01AG012546, U01AG012553, U01AG012554, U01AG012495, U19AG063720, 5R01AR081794, R01AR075729.
Albert Shieh, Marta Epeldegui, Arun S. Karlamangla, Rheinallt Jones, Roberto Pacifici, Gail A. Greendale
Original citation: J Clin Invest. 2026;136(17):e205059. https://doi.org/10.1172/JCI205059.
Citation for this corrigendum: J Clin Invest. 2026;136(21):e213400. https://doi.org/10.1172/JCI213400.
The results section has been updated to correct the upper limit of the confidence interval for the annual reported increase for FABP2. The correct text appears below.
During its period of MT-related increase (FMP –2.5 to FMP +6 years), FABP2 rose by 2.6% per year (95% CI 1.7 to 3.4%; P < 0.0001).
The HTML and PDF versions of the text have been updated online.
The authors regret the error.
See the related article at Markers of compromised gut epithelial barrier integrity increase during the menopause transition.